PAION is a specialty pharmaceutical company that develops innovative products for sedation and anesthesia including commercialization.  

 

Learn more About PAION

Remimazolam

PAION's lead compound, Remimazolam, is an ultra-short-acting intravenous Benzodiazepine sedative and anesthetic that is currently in Phase III clinical development for procedural sedation. Remimazolam has been investigated in more than 1,000 patients worldwide. 

PAION's Remimazolam

First nine months results 2016

Teleconference & webcast

09 November 2016

Replay

Presentation

news

11/09/2016

Presentation Q3 2016

Presentation Q3 2016

Read more
11/09/2016

Quarterly Statement for the first nine months of 2016

Quarterly Statement for the first nine months of 2016

Read more
10/19/2016

Press Release: Positive Remimazolam phase III colonoscopy results presented at...

Positive Remimazolam phase III colonoscopy results presented at...

Read more
10/19/2016

Press Release: Positive Remimazolam phase III colonoscopy results presented at...

Positive Remimazolam phase III colonoscopy results presented at...

Read more
09/22/2016

Press Release: Remimazolam Phase III colonoscopy data to be presented at the...

Remimazolam Phase III colonoscopy data to be presented at the...

Read more
09/06/2016

Press Release: PAION announces clinical development progress with remimazolam by...

PAION announces clinical development progress with remimazolam by...

Read more
06/29/2016

Press Release: PAION completes private placement in the amount of EUR 9.6...

PAION completes private placement in the amount of EUR 9.6...

Read more
06/19/2016

Press Release: PAION reports positive remimazolam headline data in pivotal U.S....

PAION reports positive remimazolam headline data in pivotal U.S....

Read more
04/11/2016

Press Release: PAION successfully completes patient recruitment in Phase III...

PAION successfully completes patient recruitment in Phase III...

Read more

PAION Chart